Florida Update Understanding of Leukemia Gene Therapy -->
By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- New research on Biotechnology is the subject of a report. According to news originating from Tampa, Florida, by NewsRx correspondents, research stated, "The objective of the study was to evaluate the biological validity of ovarian cancer (OVCA) screening and early detection efforts and to characterize signaling pathways associated with human cancer metastasis and patient survival. Using genome-wide expression profiling and deoxyribonucleic acid sequencing, we compared pelvic and matched extrapelvic implants from 30 patients with advanced-stage OVCA for expression of molecular signaling pathways and p53 gene mutations."
Our news journalists obtained a quote from the research from the University of Southern Florida, "Differentially expressed pathways were further evaluated in a series of primary or early-stage vs metastatic or recurrent cancer samples from 389 ovarian, prostate, and oral cancer patients. Metastasis pathways were also evaluated for associations with survival in 9 independent clinicogenomic datasets from 1691 ovarian, breast, colon, brain, and lung cancer and leukemia patients. The inhibitory effects of 1 pathway (transforming growth factor [TGF]-WNT) on in vitro OVCA cell migration were studied. Pelvic and extrapelvic OVCA implants demonstrated similar patterns of signaling pathway expression and identical p53 mutations. However, we identified 3 molecular pathways/cellular processes that were differentially expressed between pelvic and extrapelvic OVCA samples and between primary/early-stage and metastatic/advanced or recurrent ovarian, oral, and prostate cancers. Furthermore, their expression was associated with overall survival from ovarian cancer (P = .006), colon cancer (1 pathway at P = .005), and leukemia (P = .05). Artesunate-induced TGF-WNT pathway inhibition impaired OVCA cell migration. Advanced-stage OVCA has a unifocal origin in the pelvis. Molecular pathways associated with extrapelvic OVCA spread are also associated with metastasis from other human cancers and with overall patient survival."
According to the news editors, the research concluded: "Such pathways represent appealing therapeutic targets for patients with metastatic disease."
For more information on this research see: Gene expression data reveal common pathways that characterize the unifocal nature of ovarian cancer. American Journal of Obstetrics and Gynecology, 2013;209(6):205-220. American Journal of Obstetrics and Gynecology can be contacted at: Mosby-Elsevier, 360 Park Avenue South, New York, NY 10010-1710, USA. (Elsevier - www.elsevier.com; American Journal of Obstetrics and Gynecology - www.elsevier.com/wps/product/cws_home/623277)
The news correspondents report that additional information may be obtained from D.C. Marchion, University of Southern Florida, Coll Med, H Lee Moffitt Canc Center & Res Inst, Expt Therapeut Program, Tampa, FL 33612, United States. Additional authors for this research include Y. Xiong, H.S. Chon, E. Al Sawah, N.B. Zgheib, I.J. Ramirez, F. Abbasi, X.B. Stickles, P.L. Judson, A. Hakam, J. Gonzalez-Bosquet, R.M. Wenham, S.M. Apte, A.E. Berglund and J.M. Lancaster (see also technology.html">Biotechnology).
Keywords for this news article include: Biotechnology, Tampa, Florida, Genetics, Oncology, p53 Gene, Gynecology, Therapeutics, United States, Ovarian Cancer, Women's Health, Leukemia Gene Therapy, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC